此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health

2026年10月27日 更新者:International AIDS Vaccine Initiative

一项针对健康状况良好的成人进行的评估rVSV∆G-MARV-GP疫苗安全性和免疫原性的1期随机、观察者设盲、安慰剂对照、剂量递增临床试验

A Phase 1 Randomized, Observer Blind, Placebo-controlled, Dose-escalation and dose expansion Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health

研究概览

地位

主动,不招人

详细说明

This is a observer-blind, Phase 1 Randomized, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health. The study is a dose escalation study that will administer 4 different dose levels to 4 different groups. The lowest dose level will be given and then a safety assessment will occur before escalation to the next dose level. This gradual dosing followed by a safety assessment will be repeated at each dose level.

Approximately 112 participants will be given vaccine (rVSV∆G-MARV-GP) or placebo.

This IAVI C104 study will look at the safety, tolerability and immunogenicity of the rVSV Marburg virus vaccine.

研究类型

介入性

注册 (估计的)

112

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • District of Columbia
      • Washington D.C.、District of Columbia、美国、20052
        • George Washington University
    • Kansas
      • Lenexa、Kansas、美国、66219
        • Johnson County Clin-Trials

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 50年 (成人)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria

  1. Adults in good general health
  2. Participants who are 18 to 50 years of age
  3. Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study
  4. Willing to undergo HIV testing, risk reduction counseling, and receive HIV test results
  5. All sexually active participants must consistently use male or female condoms with all sexual partners for 3 months following IP administration
  6. All individuals of childbearing potential engaging in sexual activity that could lead to pregnancy must commit to use an effective method of contraception from at least 2 weeks before and continue until 3 months following receipt of vaccine/placebo
  7. All individuals of childbearing potential must be willing to undergo urine pregnancy tests at time points indicated in the Schedule of Activities (SOA)
  8. All participants must be willing to forgo donation of blood or any other tissues from screening onward throughout the course of the study

Exclusion Criteria

  1. Any clinically relevant abnormality on history or examination including:

    history of immunodeficiency or autoimmune disease history of splenectomy history of malignancy in the past 5 years use of corticosteroids, immunosuppressive, anticancer, or other medications considered significant by the Investigator within the previous 6 months body mass index (BMI) ≥ 35.0 kg/m2

  2. Any clinically significant acute or chronic medical condition that is considered progressive or in the opinion of the Investigator makes the participant unsuitable for participation in the study

  3. Individuals who are pregnant or breastfeeding

  4. Bleeding disorder that was diagnosed by a physician

  5. Infectious disease: Confirmed HIV-1 or HIV-2 infection, chronic active hepatitis B infection, current hepatitis C infection, active syphilis, or medically diagnosed long COVID 19 Syndrome. Also excluded are participants with active, serious infections requiring parenteral antibiotic, antiviral, or antifungal therapy within 30 days prior to enrollment.

  6. Any abnormal laboratory parameters at screening per protocol.

  7. Receipt of live attenuated influenza vaccine within the previous 14 days, any other live attenuated vaccine within the previous 30 days or planned receipt within 30 days after vaccination with IP; or receipt of non-live attenuated vaccine within the previous 14 days or planned receipt within 14 days after vaccination with IP, including COVID-19 vaccines

  8. Receipt of blood transfusion or blood-derived products within the previous 3 months

  9. Prior potential exposure to Marburg Virus, or a medical history of hemorrhagic fever

  10. Prior receipt of any VSV-vectored vaccine, any Marburg vaccine, or any vaccine containing a filovirus component. Prior receipt of monoclonal or polyclonal antibodies directed against Marburg or other filovirus in the past 12 months

  11. Current participation in another clinical trial, within 3 months prior to enrollment.

  12. History of severe local or systemic reactogenicity to vaccines, or severe allergy to food or medications, and/or allergy to any component of this vaccine.

  13. Neuropsychiatric condition or substance abuse that compromises safety of the participant and precludes compliance with the protocol

  14. Current or planned occupational (medical care, childcare) or household contact (residing in the same household) from screening through 3 months after IP administration with any individual at increased risk from exposure to a live viral vaccine including infants ≤ 1 year of age, adults ≥75 years of age, or immunocompromised individuals.

  15. In the opinion of the PI, it is not in the best interest of the participant to participate in the trial

  16. A history of long-term treatment (≥ 4 weeks) for arthritis

  17. Participants currently experiencing a rash or who have a history of severe, chronic, or frequent rash will be excluded.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:单组作业
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
实验性的:rVSV∆G-MARV-GP

rVSV∆G-MARV-GP

安慰剂比较:安慰剂/稀释剂

Placebo

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Safety and tolerability of rVSV∆G-MARV-GP vaccination: solicited reactogenicity
大体时间:14 Days

Occurrence, onset, duration, and severity of local and systemic solicited adverse events within 14 days following vaccination

14 Days
Safety and tolerability of rVSV∆G-MARV-GP vaccination: unsolicited reactogenicity
大体时间:28 days

Occurrence, onset, duration, severity, and relationship to IP of unsolicited adverse events, including safety laboratory parameters, within 28 days following vaccination

28 days
Safety and tolerability of rVSV∆G-MARV-GP vaccination: SAEs and AESIs
大体时间:7 Months

Occurrence, onset, duration, severity, and relationship to IP of SAEs and AESIs throughout the study period

7 Months

次要结果测量

结果测量
措施说明
大体时间
MARV-GP-specific serum antibody responses
大体时间:Throughout the study, up to 6 months after immunisation

Proportion of participants with binding antibody responses to MARV-GP

Throughout the study, up to 6 months after immunisation
MARV-GP-specific serum antibody responses magnitude and duration
大体时间:Throughout the study, up to 6 months after immunisation

Magnitude and duration of binding antibody to MARV-GP throughout the full study period (1 week, 2 weeks, 4 weeks, 2 months, 3 months, 6 months after immunization)

Throughout the study, up to 6 months after immunisation
MARV-GP-specific serum antibody neutralization
大体时间:Throughout the study, up to 6 months after immunisation

Proportion of participants with neutralizing antibody against Marburg virus as measured by PRNT assay

Throughout the study, up to 6 months after immunisation
MARV-GP-specific serum antibody magnitude and duration of neutralization
大体时间:Throughout the study, up to 6 months after immunisation

Magnitude and duration of neutralizing antibody against Marburg virus as measured by PRNT assay throughout the full study period (1 week, 2 weeks, 4 weeks, 2 months, 3 months, 6 months after immunization)

Throughout the study, up to 6 months after immunisation

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年3月27日

初级完成 (估计的)

2027年4月1日

研究完成 (估计的)

2027年10月1日

研究注册日期

首次提交

2026年2月11日

首先提交符合 QC 标准的

2026年2月19日

首次发布 (实际的)

2026年2月23日

研究记录更新

最后更新发布 (实际的)

2026年10月30日

上次提交的符合 QC 标准的更新

2026年10月27日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

其他研究编号

  • IAVI C104
  • 75A50121C00077 (其他赠款/资助编号:BARDA)

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅